Skip to main content Help with accessibility Skip to main navigation

All Guidance

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - May - 2022

Radiographic (Ankylosing Spondylitis) and Non-radiographic Axial Spondyloarthritis (ASp) LSCMMG Recommended Biologic Pathway

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2015
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2018

Denosumab 60mg injection - Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of bone loss
associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Denosumab as a second-line treatment option for the prevention of Osteoporotic Fragility Fractures

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Date Posted: 01 - December - 2018
BNF chapter: Musculoskeletal system
**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - September - 2022

For Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight in adults Information for prescribers - to be read in conjunction with the SPC

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

Treatment of active rheumatoid arthritis and active psoriatic arthritis

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted

Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic
arthritis, severe psoriatic arthritis, mild to moderate Crohn’s disease
Unlicensed: Severe Eczema, Lichen Planus, Felty’s syndrome, severe Crohn’s disease

N.B. Not all brands/formulations are licensed for all indications – please refer to individual SPCs

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

This protocol only applies to the unlicensed indications listed below. Transplant protocols should be followed for licensed indications.

Unlicensed: Severe rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, connective tissue diseases with severe / organ-threatening manifestations, interstitial lung disease (not to be used in idiopathic pulmonary fibrosis IPF), vasculitidies, as maintenance post cyclophosphamide in patients for whom azathioprine is contra-indicated or is inappropriate.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted

Guidance on consensus approaches to managing Palliative Care Symptoms

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

Licensed: Severe active rheumatoid arthritis, including juvenile forms, Wilson's disease (hepatolenticular degeneration) in adults and children (0 to 18 years).

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2017
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2015
BNF chapter: Musculoskeletal system

The purpose of these guidelines is to provide a quick reference guide for use in primary care summarising information on the diagnosis and management of RLS in primary care. This guidance covers the management of RLS in primary care and gives information about when to refer to secondary care. 

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - August - 2019
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

Licensed – Active, progressive rheumatoid arthritis, progressive juvenile chronic arthritis especially if polyarticular or seropositive.
Unlicensed – skin diseases including pemphigus

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted

Licensed: Rheumatoid arthritis; ulcerative colitis, Crohn’s disease in adults and children
Unlicensed: Sero-negative spondyloarthropathy including psoriatic arthritis and psoriasis.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***